Understanding the mechanisms of stroke subtypes associated with glycoprotein IIb/IIIa inhibitors is important for improving outcomes in cardiac patients and translating strategies to cerebrovascular disease.
Emphasizes mechanistic research needs for GP IIb/IIIa inhibitor strokes; leaves open evidence-based strategies for cardiac and cerebrovascular patients.
Ischemic and hemorrhagic subtypes of stroke are important complications of treatments for cardiac disease, as they impact significantly on patient management and outcome. Their frequency varies with the characteristics of the patient population under study, the procedures involved, and the combination and intensity of antiplatelet, antithrombotic, and fibrinolytic strategies employed. Understanding the mechanisms contributing to the various stroke subtypes is important, not only to improve the overall outcome for patients with cardiac disease, but also to translate similar strategies to patients with cerebrovascular disease, for whom the risk-to-benefit ratio is more acute.
No takes yet. Share an insight, caveat, or question.
Cathy Sila (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: